Literature DB >> 21345263

Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.

Pedro Póvoa1, João Gonçalves-Pereira.   

Abstract

In 2009 the Infectious Diseases Society of America reviewed the guidelines on the treatment of candidemia in non-neutropenic patients. In this document the preferred treatment was either fluconazole or an echinocandin. Amphotericin-B formulations were considered an alternative. However, careful assessment of published data showed similar efficacy between these drugs.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21345263      PMCID： PMC3222043          DOI： 10.1186/cc9414

Source DB:  PubMed          Journal:  Crit Care        ISSN： 1364-8535            Impact factor:   9.097


  15 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

Review 2.  Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.

Authors:  Sanjay Kaul; George A Diamond
Journal:  Prog Cardiovasc Dis       Date:  2007 Jan-Feb       Impact factor: 8.194

Review 3.  Echinocandins for candidemia in adults without neutropenia.

Authors:  John E Bennett
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

4.  Lessons from and cautions about noninferiority and equivalence randomized trials.

Authors:  Peter C Gøtzsche
Journal:  JAMA       Date:  2006-03-08       Impact factor: 56.272

Review 5.  Amphotericin B nephrotoxicity.

Authors:  Gilbert Deray
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 6.  Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.

Authors:  H K Johansen; P C Gotzsche
Journal:  Cochrane Database Syst Rev       Date:  2000

7.  Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

Authors:  J R Wingard; P Kubilis; L Lee; G Yee; M White; L Walshe; R Bowden; E Anaissie; J Hiemenz; J Lister
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

8.  In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.

Authors:  Giovanni Di Bonaventura; Ilaria Spedicato; Carla Picciani; Domenico D'Antonio; Raffaele Piccolomini
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

9.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

10.  Patterns of amphotericin B killing kinetics against seven Candida species.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
View more
  2 in total

1.  Echinocandins--first line in invasive candidiasis: how strong is this 'strong' evidence?

Authors:  João Gonçalves-Pereira; Pedro Póvoa
Journal:  Crit Care       Date:  2011-12-15       Impact factor: 9.097

2.  Treatment of invasive candidiasis in the elderly: a review.

Authors:  Aikaterini Flevari; Maria Theodorakopoulou; Aristea Velegraki; Apostolos Armaganidis; George Dimopoulos
Journal:  Clin Interv Aging       Date:  2013-09-09       Impact factor: 4.458
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.